First read for a new ticker takes about 20–30 seconds while we build the analysis from the latest fundamentals, estimates, and intelligence. It's saved after this, so future visits are instant.
Thesis: Ono Pharmaceutical: the story is balanced — Opdivo sales trajectory in Japan - quarterly prescription data and market share versus Merck's Keytruda in key oncology…
★ Analysts see FY2028 revenue reaching $451.7B — -2.1% growth in a single year.
What Moves the Stock
1Opdivo sales trajectory in Japan - quarterly prescription data and market share versus Merck's Keytruda in key oncology indications (lung, gastric, renal cell carcinoma)
2Pipeline readouts for ONO-4578 (prostaglandin receptor antagonist for autoimmune diseases) and other mid-stage assets - Phase 2/3 data releases drive significant volatility
3Japanese drug pricing policy changes - biennial National Health Insurance price revisions directly impact revenue (next major revision April 2026)
value - Stock trades at modest multiples (2.4x P/S, 10.1x EV/EBITDA) reflecting mature product portfolio and patent cliff concerns…
Rising rates have modest negative impact through two channels: (1) higher discount rates compress valuation multiples for long-duration…
Watch on earnings: Quarterly Opdivo prescription volume data in Japan (IMS/IQVIA data) - leading indicator of revenue trends, Bristol Myers Squibb quarterly Opdivo global sales (reported in BMS earnings) - drives royalty revenue, Japanese Ministry of Health drug pricing revision announcements (April 2026 revision imminent) - direct P&L impact.
One Sentence Summary:
Ono Pharmaceutical: the story is balanced — opdivo sales trajectory in japan - quarterly prescription data and market share versus merck's keytruda in key oncology indications (lung.
Auto-composed from Stock Alarm intelligence, financial statements, and analyst estimates. Not investment advice.